Bull
$18.62
Scenario price
$57.750
-0.485 (-0.84%)At close
Calumet, Inc. manufactures, formulates, and markets a diversified slate of specialty branded products and renewable fuels to customers across a range of consumer-facing and industrial markets. Its segments include Specialty Products and Solutions, Montana/Renewables, and Performance Brands. The Specialty Products and Solutions segment consists of its customer-focused solutions and formulations businesses, covering multiple specialty product lines, anchored by its integrated complex in Northwest Louisiana. In this segment, it manufactures and markets a variety of solvents, waxes, customized lubricating oils, white oils, gels, esters, and other products. The Montana/Renewables segment is composed of its Montana Renewables facility and its Great Falls specialty asphalt facility. The Performance Brands segment includes its portfolio of high-performing brands. In this segment, it blends, packages, and markets high-performance products through its Royal Purple, Bel-Ray, and TruFuel brands.
Calumet Specialty Products Partners LP is a good buy right now due to its current price of $56.42, which is below the analyst price target of $75 from H.C. Wainwright. Additionally, the company recently secured full EPA exemptions, which could enhance its financials by approximately $309 million, significantly improving its profitability outlook. However, the forward P/E ratio of 49.02 indicates that the stock may be overvalued if growth does not materialize as expected, posing a risk to investors.
H.C. Wainwright
$75
2026-09-02
H.C. Wainwright
2026-09-02
Price Target
$75
BofA
$60
2026-09-01
BofA
2026-09-01
Price Target
$60
UBS
$47
2026-08-25
UBS
2026-08-25
Price Target
$47
TD Cowen
$40
2026-08-12
TD Cowen
2026-08-12
Price Target
$40
BofA
$45
2026-08-10
BofA
2026-08-10
Price Target
$45
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Calumet Announces Redemption of $150 Million Debt

Calumet to Report Q3 2026 Results on November 6

Calumet to Report Q3 2026 Results on November 6

Calumet Increases Loan Facility to $600 Million

Calumet Increases Asset-Based Loan Facility to $600 Million
Calumet, Inc. manufactures, formulates, and markets a diversified slate of specialty branded products and renewable fuels to customers across a range of consumer-facing and industrial markets. Its segments include Specialty Products and Solutions, Montana/Renewables, and Performance Brands. The Specialty Products and Solutions segment consists of its customer-focused solutions and formulations businesses, covering multiple specialty product lines, anchored by its integrated complex in Northwest Louisiana. In this segment, it manufactures and markets a variety of solvents, waxes, customized lubricating oils, white oils, gels, esters, and other products. The Montana/Renewables segment is composed of its Montana Renewables facility and its Great Falls specialty asphalt facility. The Performance Brands segment includes its portfolio of high-performing brands. In this segment, it blends, packages, and markets high-performance products through its Royal Purple, Bel-Ray, and TruFuel brands. It operates in the Energy sector (PETROLEUM REFINING industry).
Calumet Specialty Products Partners LP is a good buy right now due to its current price of $56.42, which is below the analyst price target of $75 from H.C. Wainwright. Additionally, the company recently secured full EPA exemptions, which could enhance its financials by approximately $309 million, significantly improving its profitability outlook. However, the forward P/E ratio of 49.02 indicates that the stock may be overvalued if growth does not materialize as expected, posing a risk to investors.
5 analysts cover CLMT: 1 rate it Buy, 3 Hold and 1 Sell. The average price target is 23.67.

Wall St is expecting 1.55 EPS for $CLMT Q3 [Reporting 11/06 BMO]
Show moreThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.